Britain's regulators are being urged to rapidly approve new Alzheimer's drugs that have been hailed as a 'turning point' in the fight against the disease. Donanemab was found to significantly delay the worsening of symptoms in people with early stage Alzheimer's in a landmark trial. The drug also slowed the progress of the disease by up to 60 per cent. It follows lecanemab to be the second drug to offer hope to patients and raises the prospect of the disease one day being treated like asthma or